滤泡性淋巴瘤——治疗与预后因素
Follicular lymphoma - treatment and prognostic factors.
作者信息
Luminari Stefano, Bellei Monica, Biasoli Irene, Federico Massimo
机构信息
Department of Oncology, Hematology and respiratory diseases, L'Università di Modena e Reggio Emilia - UniMoRe, Modena, Italy.
出版信息
Rev Bras Hematol Hemoter. 2012;34(1):54-9. doi: 10.5581/1516-8484.20120015.
Abstract
Follicular lymphoma is the second most frequent non-Hodgkin lymphoma accounting for about 10-20% of all lymphomas in western countries. The median age at diagnosis is 60 years old. The clinical presentation is usually characterized by asymptomatic peripheral adenopathy in cervical, axillary, inguinal and femoral regions. Treatment options for patients with naïve or recurrent follicular lymphoma are still controversial, ranging from a "watch and wait" policy to hematopoietic stem cell transplantation. More recently, the availability of rituximab has substantially changed follicular lymphoma therapeutic approaches to such an extent that R-Chemo is now the standard induction first-line treatment. This review provides a general overview of the state of the art in the management of follicular lymphoma and also, a brief description regarding the current prognostic tools available for treatment decisions.
摘要
滤泡性淋巴瘤是第二常见的非霍奇金淋巴瘤，在西方国家约占所有淋巴瘤的10%-20%。诊断时的中位年龄为60岁。临床表现通常以颈部、腋窝、腹股沟和股部无症状的外周淋巴结病为特征。初治或复发滤泡性淋巴瘤患者的治疗选择仍存在争议，范围从“观察等待”策略到造血干细胞移植。最近，利妥昔单抗的出现极大地改变了滤泡性淋巴瘤的治疗方法，以至于R-化疗现在是标准的诱导一线治疗。本综述概述了滤泡性淋巴瘤管理的最新进展，并简要描述了目前可用于治疗决策的预后工具。
相似文献
1
Follicular lymphoma - treatment and prognostic factors.滤泡性淋巴瘤——治疗与预后因素
Rev Bras Hematol Hemoter. 2012;34(1):54-9. doi: 10.5581/1516-8484.20120015.
2
Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.澳大利亚非霍奇金淋巴瘤的一线治疗。第 1 部分：滤泡性淋巴瘤。
Intern Med J. 2019 Apr;49(4):422-433. doi: 10.1111/imj.14113.
3
The therapeutic use of rituximab in non-Hodgkin's lymphoma.利妥昔单抗在非霍奇金淋巴瘤中的治疗应用。
Eur J Haematol Suppl. 2007 Jan(67):5-14. doi: 10.1111/j.1600-0609.2006.00789.x.
4
Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.外周血淋巴细胞/单核细胞比值可预测利妥昔单抗时代滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤患者的预后。
Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):208-13. doi: 10.1016/j.clml.2014.10.001. Epub 2014 Oct 23.
5
Follicular lymphomas.滤泡性淋巴瘤
Crit Rev Oncol Hematol. 2008 Jun;66(3):248-61. doi: 10.1016/j.critrevonc.2008.01.014. Epub 2008 Mar 21.
6
High-dose chemotherapy followed by autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular non-Hodgkin’s lymphoma in the rituximab era.利妥昔单抗时代滤泡性非霍奇金淋巴瘤患者接受大剂量化疗后进行自体和异基因造血干细胞移植
Tumori. 2015 Jan-Feb;101(1):2-7. doi: 10.5301/tj.5000203.
7
Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.脾边缘区淋巴瘤：预后因素、观察等待策略的作用以及利妥昔单抗时代的其他治疗方法
Leuk Res. 2016 May;44:53-60. doi: 10.1016/j.leukres.2016.03.005. Epub 2016 Mar 22.
8
Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.滤泡性淋巴瘤和转化型滤泡性淋巴瘤自体干细胞移植的长期随访
Eur J Haematol. 2000 Jul;65(1):17-22. doi: 10.1034/j.1600-0609.2000.90114.x.
9
Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.利妥昔单抗：在慢性淋巴细胞白血病、低级别或滤泡性淋巴瘤以及弥漫性大 B 细胞淋巴瘤中的应用综述。
Drugs. 2010 Jul 30;70(11):1445-76. doi: 10.2165/11201110-000000000-00000.
10
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.在接受 6 个周期 CHOP 治疗的侵袭性 B 细胞淋巴瘤患者中，使用利妥昔单抗 6 或 8 个剂量：来自“侵袭性非霍奇金淋巴瘤正电子发射断层扫描引导治疗”（PETAL）试验的结果。
Ann Hematol. 2019 Apr;98(4):897-907. doi: 10.1007/s00277-018-3578-0. Epub 2019 Jan 4.
引用本文的文献
1
Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy.用于战斗的活体药物：嵌合抗原受体T细胞疗法综述
Int J Hematol Oncol Stem Cell Res. 2025 Apr 1;19(2):180-190. doi: 10.18502/ijhoscr.v19i2.18555.
2
Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches.利用基于蛋白质的方法对人类 B 细胞血液系统恶性肿瘤进行表征。
Int J Mol Sci. 2024 Apr 24;25(9):4644. doi: 10.3390/ijms25094644.
3
Therapeutic Vaccines for Follicular Lymphoma: A Systematic Review.滤泡性淋巴瘤的治疗性疫苗：一项系统评价
Pharmaceuticals (Basel). 2024 Feb 21;17(3):272. doi: 10.3390/ph17030272.
4
Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: A Cost-Effectiveness Analysis.在既往未经治疗的意大利中高危晚期滤泡性淋巴瘤患者中，奥比妥珠单抗联合化疗与利妥昔单抗联合化疗的成本效益分析
Clinicoecon Outcomes Res. 2021 Jul 22;13:661-671. doi: 10.2147/CEOR.S317885. eCollection 2021.
5
Case Report: Spontaneous Remission of an Infraorbital Follicular B-Cell Lymphoma: Case Report and Review of the Literature.病例报告：眶内滤泡 B 细胞淋巴瘤的自发缓解：病例报告及文献复习。
Pathol Oncol Res. 2021 Apr 8;27:642433. doi: 10.3389/pore.2021.642433. eCollection 2021.
6
Function of Deptor and its roles in hematological malignancies. Deptor 的功能及其在血液恶性肿瘤中的作用。
Aging (Albany NY). 2021 Jan 7;13(1):1528-1564. doi: 10.18632/aging.202462.
7
MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers.miR-144：癌症中一个新的可能的治疗靶点和诊断/预后工具。
Int J Mol Sci. 2020 Apr 8;21(7):2578. doi: 10.3390/ijms21072578.
8
Incidence and mortality trends and geographic patterns of follicular lymphoma in Canada.加拿大滤泡性淋巴瘤的发病和死亡趋势及地理模式。
Curr Oncol. 2019 Aug;26(4):e473-e481. doi: 10.3747/co.26.4625. Epub 2019 Aug 1.
9
Thoracoscopic Diagnosis of Follicular Lymphoma Relapsing after 13 Years.13年后复发性滤泡性淋巴瘤的胸腔镜诊断
Surg J (N Y). 2019 Feb 14;5(1):e5-e7. doi: 10.1055/s-0038-1661416. eCollection 2019 Jan.
10
Characteristics of follicular and mantle cell lymphoma in Brazil: prognostic impact of clinical parameters and treatment conditions in two hospitals.巴西滤泡性和套细胞淋巴瘤的特征：两家医院临床参数和治疗条件的预后影响
Hematol Transfus Cell Ther. 2018 Oct-Dec;40(4):343-353. doi: 10.1016/j.htct.2018.02.004. Epub 2018 Apr 18.
本文引用的文献
1
Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.利妥昔单抗维持治疗滤泡性淋巴瘤患者：一项更新的随机试验系统评价和荟萃分析。
J Natl Cancer Inst. 2011 Dec 7;103(23):1799-806. doi: 10.1093/jnci/djr418. Epub 2011 Oct 21.
2
Follicular lymphoma: 2011 update on diagnosis and management.滤泡性淋巴瘤：诊断与治疗的 2011 年更新。
Am J Hematol. 2011 Sep;86(9):768-75. doi: 10.1002/ajh.22099.
3
Treatment strategies in advanced stage follicular lymphoma.晚期滤泡性淋巴瘤的治疗策略。
Best Pract Res Clin Haematol. 2011 Jun;24(2):187-201. doi: 10.1016/j.beha.2011.03.003. Epub 2011 May 8.
4
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.利妥昔单抗维持治疗对利妥昔单抗联合化疗后高肿瘤负荷滤泡性淋巴瘤患者的影响（PRIMA）：一项 3 期随机对照试验。
Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7. Epub 2010 Dec 20.
5
Prognostic tools in follicular lymphomas.滤泡性淋巴瘤的预后工具。
Expert Rev Hematol. 2009 Oct;2(5):549-62. doi: 10.1586/ehm.09.34.
6
Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis.早期低级别滤泡淋巴瘤患者接受放疗后生存改善：监测、流行病学和最终结果数据库分析。
Cancer. 2010 Aug 15;116(16):3843-51. doi: 10.1002/cncr.25149.
7
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.滤泡性淋巴瘤国际预后指数2：由国际滤泡性淋巴瘤预后因素项目制定的滤泡性淋巴瘤新预后指数。
J Clin Oncol. 2009 Sep 20;27(27):4555-62. doi: 10.1200/JCO.2008.21.3991. Epub 2009 Aug 3.
8
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.钇-90 替伊莫单抗巩固治疗与晚期滤泡性淋巴瘤首次缓解后不进行额外治疗对比的 III 期试验。
J Clin Oncol. 2008 Nov 10;26(32):5156-64. doi: 10.1200/JCO.2008.17.2015. Epub 2008 Oct 14.
9
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.利妥昔单抗联合化疗及干扰素治疗滤泡性淋巴瘤患者：GELA-GOELAMS FL2000研究结果
Blood. 2008 Dec 15;112(13):4824-31. doi: 10.1182/blood-2008-04-153189. Epub 2008 Sep 17.
10
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.R-CVP与单纯环磷酰胺、长春新碱和泼尼松相比，用于既往未治疗的晚期滤泡性淋巴瘤患者的III期研究。
J Clin Oncol. 2008 Oct 1;26(28):4579-86. doi: 10.1200/JCO.2007.13.5376. Epub 2008 Jul 28.
Zotero 插件